The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from the team at ARK Invest that tries to pick the companies best positioned to profit from advancements in energy, automation, manufacturing, materials and transportation.
The advisory firm, led by Catherine Wood, has an impressive track record doing what most stock pickers fail to do: beating the market.
ARKG invests in companies that could profit from technological and scientific advancements in gene editing, genetic therapy, molecular diagnostics, and stem cell advances.
It’s a niche product without a lot of competition. ARKG’s nearest rival is likely the iShare Genomics immunology and Healthcare ETF, an index-tracking ETF that launched in June 2019.
Beyond the active/passive difference, IDNA’s holdings are dominated by major pharmaceutical firms like Moderna, Regeneron and Gilead Sciences, whereas ARKG’s portfolio is tilted toward significantly smaller firms.
There isn’t a lot of performance history to compare, but it’s worth nothing that IDNA beat ARKG in the first ten weeks of 2020, when global markets were rocked by the coronavirus outbreak and investors were eagerly hunting for potential profit in companies researching treatment and vaccines.
But that’s just a fleeting snapshot during a particularly turbulent time. Any actively-managed product is ultimately a bet on the portfolio managers who pick the stocks. ARK’s products are geared toward investors who have the fortitude and faith to ride out short-term blips in favor of the prospect long-term alpha.
| Segment | Equity: Global Genomic Advancements |
| Category | Sector |
| Focus | Theme |
| Niche | Genomic Advancements |
| Strategy | Active |
| Weighting Scheme | Proprietary |
This section compares how balanced and deep this ETF is relative to its peers.
| ARKG | ETF Database Category Average | FactSet Segment Average | |
|---|---|---|---|
| Number of Holdings | 50 | 92 | 48 |
| % of Assets in Top 10 | 47.29% | 44.55% | 46.28% |
| % of Assets in Top 15 | 62.97% | 57.55% | 61.84% |
| % of Assets in Top 50 | 99.97% | 91.26% | 99.44% |
| ARKG | ETF Database Category Average | FactSet Segment Average | |
|---|---|---|---|
| Large (>12.9B) | 12.62% | 49.39% | 27.83% |
| Mid (>2.7B) | 38.66% | 24.15% | 28.29% |
| Small (>600M) | 33.25% | 17.94% | 18.60% |
| Micro (<600M) | 15.01% | 5.79% | 4.90% |
This section compares the P/E ratio of this ETF to its peers.
This section compares the dividend yield of this ETF to its peers.
| ARKG | ETF Database Category Average | FactSet Segment Average | |
|---|---|---|---|
| Dividend | $ 0.79 | $ 0.16 | $ 0.19 |
| Dividend Date | 2020-12-29 | N/A | N/A |
| Annual Dividend Rate | $ 0.79 | $ 0.41 | $ 0.19 |
| Annual Dividend Yield | 1.07% | 0.36% | 0.30% |
View charts featuring ARKG price and volume data.
View charts featuring ETF fund flow data.
5 Day Net Flows: -8.74 M 1 Month Net Flows: -22.83 M 3 Month Net Flows: -160.48 M 6 Month Net Flows: -257.15 M 1 Year Net Flows: -584.42 M 3 Year Net Flows: 5.97 B 5 Year Net Flows: 6.32 B 10 Year Net Flows: 6.37 BView charts that break down the influence that fund flows and price had on overall assets.
5 Day Net AUM Change: -146.18 MThe adjacent table gives investors an individual Realtime Rating for ARKG on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETF Database Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETF Database Pro. To view information on how the ETF Database Realtime Ratings work, click here.
This section compares the cost efficiency of this ETF to its peers.
| Max ST Capital Gains Rate | 39.60% |
| Max LT Capital Gains Rate | 20.00% |
| Tax On Distributions | Qualified dividends |
| Distributes K1 | No |
This section shows how this ETF has performed relative to its peers.
| ARKG |
ETF Database
Category Average |
Factset Segment
Average |
|
|---|---|---|---|
| 1 Month Return | -1.01% | 4.84% | 3.05% |
| 3 Month Return | -12.31% | 2.57% | -4.02% |
| YTD Return | -48.95% | -15.55% | -31.10% |
| 1 Year Return | -51.69% | -13.61% | -33.00% |
| 3 Year Return | -2.66% | 9.58% | -5.26% |
| 5 Year Return | 36.78% | 25.18% | 7.36% |
The following charts reflect the geographic spread of ARKG's underlying holdings.
| Region | Percentage |
|---|---|
| North, Central and South America | 99.95% |
| Other | 0.02% |
| Country | Percentage |
|---|---|
| United States | 92.52% |
| Switzerland | 3.72% |
| Canada | 1.91% |
| Germany | 0.89% |
| United Kingdom | 0.55% |
| Other | 0.38% |
The following charts reflect the allocation of ARKG's underlying holdings.
| Sector | Percentage |
|---|---|
| Health Technology | 74.73% |
| Technology Services | 10.7% |
| Health Services | 10.52% |
| Electronic Technology | 1.42% |
| Commercial Services | 1.14% |
| Process Industries | 1.08% |
| Miscellaneous | 0.36% |
| Other | 0.02% |
| CASH | 0.0% |
| Market Cap | Percentage |
|---|---|
| Mid | 38.66% |
| Small | 33.25% |
| Micro | 15.01% |
| Large | 12.62% |
| Region | Percentage |
|---|
| Asset | Percentage |
|---|---|
| Share/Common/Ordinary | 99.04% |
| American Depositary Receipt | 0.55% |
| Open-ended Fund | 0.36% |
| Other | 0.02% |
| CASH | 0.0% |
| Sector | Percentage |
|---|---|
| Health Technology | 74.73% |
| Technology Services | 10.7% |
| Health Services | 10.52% |
| Electronic Technology | 1.42% |
| Commercial Services | 1.14% |
| Process Industries | 1.08% |
| Miscellaneous | 0.36% |
| Other | 0.02% |
| CASH | 0.0% |
This section shows how the volatility of this ETF compares to the peer group ETF Database Category.
| 5 Day Volatility | 58.05% |
| 20 Day Volatility | 59.03% |
| 50 Day Volatility | 53.91% |
| 200 Day Volatility | 52.82% |
| Beta | 1.58 |
| Standard Deviation | 8.86% |
ETF Database's Financial Advisor Reports are designed as an easy handout for clients to explain the key information on a fund. Includes new analyst insights and classification data.
Fact sheets are issued by the ETF provider and framed by ETF Database. Information contained within the fact sheet is not guaranteed to be timely or accurate.
It’s been six months since I joined the company now known to many as VettaFi as head of research....
Here is a look at the 25 best and 25 worst ETFs from the past week. Traders can use this list to...
Here is a look at ETFs that currently offer attractive short selling opportunities.
The ETFs...
ETF Trends and ETF Database , the preeminent digital platforms for ETF news, research, tools, video, webcasts, native content channels, and more. The ETF Trends and ETF Database brands have been trusted amongst advisors, institutional investors, and individual investors for a combined 25 years. The firms are uniquely positioned to aid advisor’s education, adoption, and usage of ETFs, as well as the asset management community’s transition from traditionally analog to digital interactions with the advisor community.
Our team at ETF Database is committed to making our website the premier source of information on ETF investing with the world’s highest quality ETF tools, content, and resources.
ETF Database analysts have a combined 50 years in the ETF and Financial markets, covering every asset class and investment style. The team monitors new filings, new launches and new issuers to make sure we place each new ETF in the appropriate context so Financial Advisors can construct high quality portfolios.
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
A long-running debate in asset allocation circles is how much of a portfolio an investor should...
In a digital age where information moves in milliseconds and millions of participants can transact...